Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Glehr, M; Leithner, A; Scheipl, S; Zacherl, M; Quehenberger, F; Maurer-Ertl, W; Gruber, G; Beham, A; Windhager, R.
Liposarcomas: treatment and outcome, a retrospective single-center study
EUR SURG. 2009; 41(4): 163-169. Doi: 10.1007/s10353-009-0477-6
Web of Science FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Glehr Mathias
Co-Autor*innen der Med Uni Graz
Beham Alfred
Gruber Gerald
Leithner Andreas
Maurer-Ertl Werner
Quehenberger Franz
Scheipl Susanne
Windhager Reinhard
Zacherl Maximilian

Dimensions Citations:
Plum Analytics:

Scite (citation analytics):

BACKGROUND: In liposarcoma (LS), tumor-grade, histopathologic subtype, size, and completeness of resection are important prognostic factors. METHODS: We analyzed 80 patients with LS in an unselected patient sample concerning local recurrence, metastases, and survival in relation to clinicopathological characteristics and treatment. RESULTS: The five-year event-free rate was 82%. The strongest predictive prognostic factor was tumor grading. There was a significant influence of age over 60 showing a worse prognosis. Within 5 years after diagnosis, metastases were diagnosed in 13.1% (95% CI from 2.9% to 22.2%). The mean interval from first diagnosis to metastases was 27 months (0 to 63 months). Local recurrence occurred just in patients, who were not primary treated in a tumor-center and first resection was inadequate (five LS G II and one LS G I). CONCLUSIONS: Prognosis of LS is good if surgical treatment is adequate and resection performed with clear margins. Patients with suspected LS should be referred to specialized tumor-centers.

Find related publications in this database (Keywords)
lipomatous tumor
soft tissue sarcoma
© Med Uni Graz Impressum